Related Experiment Videos
Recombinant virus like particles as drug delivery system
Christiane Georgens1, Jörg Weyermann, Andreas Zimmer
1Institute of Pharmaceutical Sciences, Karl-Franzens-University Graz, Schubertstrasse 6, 8010 Graz, Austria.
Current Pharmaceutical Biotechnology
|February 25, 2005
Summary
Virus-like particles made from Polyomavirus VP1 protein offer a safe, non-pathogenic drug delivery system. These particles can target specific receptors and bind drugs for gene therapy, vaccines, and small molecule delivery.
Area of Science:
- Biotechnology
- Virology
- Nanotechnology
Background:
- Polyomavirus forms non-enveloped icosahedral capsids (approx. 50 nm diameter) using VP1, VP2, and VP3 proteins.
- The major capsid protein, VP1, is arranged in pentamers forming the outer shell and mediates receptor binding.
- VP1 contains DNA-binding and nuclear localization domains, suggesting potential for gene delivery.
Purpose of the Study:
- To describe a novel drug delivery system based on Polyomavirus VP1 protein.
- To highlight the potential of VP1 as a safe, non-pathogenic pharmaceutical excipient.
- To explore VP1's utility as a drug carrier for gene therapy and other applications.
Main Methods:
- Recombinant expression of the major capsid protein (VP1) of Polyomavirus.
- Characterization of VP1 for its potential as a drug carrier.
- Investigation of VP1's targeting and drug-binding capabilities.
Main Results:
- Recombinant VP1 protein can be produced safely and in high purity.
- VP1 protein functions as a ligand for cellular receptors, enabling targeting.
- VP1 provides both a targeting mechanism and a drug binding site.
Conclusions:
- Recombinant VP1 protein is a promising, safe excipient for drug delivery systems.
- VP1-based virus-like particles can be utilized for targeted delivery of genes, oligonucleotides, small molecules, and vaccines.
- This approach offers a novel platform for advanced therapeutic applications.